Skip to main content
. 2022 Nov 9;13:1002834. doi: 10.3389/fendo.2022.1002834

Table 1.

Patient demographics.

Total (n = 4462) Metformin (n = 1021) No Metformin (n = 3441) p-value
Age, mean (SD) 64.38 (16.19) 67.14 (12.47) 63.56 (17.01) <0.0001
Gender, n (%) 0.53
Male 2367 (53.1) 533 (52.2) 1834 (53.3)
Female 2094 (46.9) 488 (47.8) 1606 (46.7)
Race, n (%) <0.01
White 461 (11.3) 89 (9.5) 372 (11.9)
Black 1681 (41.3) 395 (42.1) 1286 (41.0)
Asian 111 (2.7) 39 (4.2) 72 (2.3)
Other 1822 (44.7) 416 (44.3) 1406 (44.8)
Ethnicity, n (%) 0.33
Hispanic 1659 (41.5) 366 (40.1) 1293 (41.9)
Non-Hispanic 2341 (58.5) 547 (59.9) 1794 (58.1)
Hypertension, n (%) <0.0001
Yes 1886 (42.3) 594 (58.2) 1292 (37.5)
No 2576 (57.7) 427 (41.8) 2149 (62.5)
Peripheral Artery Disease, n (%) 0.06
Yes 50 (1.1) 17 (1.7) 33 (1.0)
No 4412 (98.9) 1004 (98.3) 3408 (99.0)
Coronary Artery Disease, n (%) <0.0001
Yes 366 (8.2) 137 (13.4) 229 (6.7)
No 4096 (91.8) 884 (86.6) 3212 (93.3)
BMI, mean (SD) 29.62 (7.46) 30.45 (7.67) 29.36 (7.38) <0.0001
Chronic Kidney Disease, n (%) 0.71
Yes 313 (7.0) 69 (6.8) 244 (7.1)
No 4149 (93.0) 952 (93.2) 3197 (92.9)
Sulfonylurea, n (%) <0.0001
Yes 424 (9.5) 301 (29.5) 123 (3.6)
No 4038 (90.5) 720 (70.5) 3318 (96.4)
DPP4 Inhibitor, n (%) <0.0001
Yes 529 (11.9) 372 (36.4) 157 (4.6)
No 3933 (88.1) 649 (63.6) 3284 (95.4)
GLP-1 Agonist, n (%)
Yes
177 (4.0) 118 (11.6) 59 (1.7) <0.0001
No 4285 (96.0) 903 (88.4) 3382 (98.3)
SGLT-2 Inhibitor, n (%) <0.0001
Yes 86 (1.9) 71 (7.0) 15 (0.4)
No 4376 (98.1) 950 (93.0) 3426 (99.6)
Insulin, n (%) <0.0001
Yes 780 (17.5) 374 (36.6) 406 (11.8)
No 3682 (82.5) 647 (63.4) 3035 (88.2)
HbA1c, mean (SD) 7.02 (2.04) 8.21 (2.12) 6.52 (1.79) <0.0001
Anion Gap, mean (SD) 16.72 (4.68) 17.06 (4.67) 16.62 (4.68) <0.01
Creatinine, mean (SD) 2.02 (2.61) 1.62 (1.67) 2.14 (2.82) <0.0001
eGFR, mean (SD) 56.00 (31.04) 57.37 (28.33) 55.59 (31.82) 0.09
Number of Medications, mean (SD) 0.45 (0.85) 1.21 (1.11) 0.22 (0.58) <0.0001